A Selection of Recent Papers

Metastatic Biomarker Discovery Through Proteomics. L.T. BRINTON, T.A. BRENTNALL, J.A. SMITH, K.A. KELLY (Charlottesville, VA; Seattle, WA, USA)


Review: Breast Cancer and Metastasis: On the Way Toward Individualized Therapy. A.P. TRAPÉ, A.M. GONZALEZ-ANGULO (Houston, TX, USA)

In Silico Functional Profiling of Individual Prostate Cancer Tumors: Many Genes, Few Functions. I.P. GORLOV, J. BYUN, C.J. LOGOTHETIS (Houston, TX, USA)

Expression of Signal-induced Proliferation-associated Gene 1 (SIPA1), a RapGTPase-activating Protein, Is Increased in Colorectal Cancer and Has Diverse Effects on Functions of Colorectal Cancer Cells. K. JI, L. YE, A.-M. TOMS, R. HARGEST, T.A. MARTIN, F. RUGE, J. JI, W.G. JIANG (Cardiff, UK; Beijing, PR China)

Single Nucleotide Polymorphisms of Genes for EGF, TGF-β and TNF-α in Patients with Pancreatic Carcinoma. L. ZHANG, G. WU, F. HERRLE, M. NIEDERGETHMANN, M. KEESE (Frankfurt; Heidelberg, Germany; Xiamen, P.R. China)

Diagnostic MicroRNA Markers to Screen for Sporadic Human Colon Cancer in Blood. F.E. AHMED, N.C. AMED, P.W. VOS, C. BONNERUP, J.N. ATKINS, M. CASEY, G.J. NUOVO, W. NAZIRI, J.E. WILEY, R.R. ALLISON (Greenville, Goldsboro, NC; Columbus, OH, USA)

MGMT Hypermethylation and MDR System in Glioblastoma Cancer Stem Cells. V. CALDERA, M. MELLAI, L. ANNOVAZZI, O. MONZEGLIO, A. PIAZZI, D. SCHIFFER (Pavia; Novara, Italy)

20-HETE-producing Enzymes Are Up-regulated in Human Cancers. A. ALEXANIAN, B. MILLER, R.J. ROMAN, A. SOROKIN (Milwaukee, WI; Jackson, MS, USA)

Unifying the Genomics-based Classes of Cancer Fusion Gene Partners: Large Cancer Fusion Genes are Evolutionarily Conserved. L.M. PAVA, D.T. MORTON, R. CHEN, G. BLANCK (Tampa, FL, USA)
Instructions to Authors 2013

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):
1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:
   John G. Delineasios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH,
   IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2013 - International Institute of Anticancer Research (J.G. Delineasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
Subscription Order Form 2013

☐ Please enter a Subscription to ANTICANCER RESEARCH for Volume 33 (2013).
Annual subscription rates (2013): Institutional, Euro 1,650.00 print or online; Personal, Euro 780.00 print or online;
Prices include rapid delivery and insurance.
2013 online subscriptions include free online access to vol. 24 (2004) - 32 (2012).

☐ Please send me the following previous volumes (1-32) at 50% discount on the above rates.

☐ Payment is enclosed.  ☐ Please invoice.
(Checks should be made payable to J.G. Delinasios, Athens, Greece)
☐ Please send me information about the International Institute of Anticancer Research (IIAR).

Name and Address: ..........................................................................................................................................................................
Tel: ............................................................................................................................................................................................
Fax: ......................................................................................................................................................................................
Signature: ............................................................................................................................................................................
Date: ................................................................................................................................................................................

Please send this order to ANTICANCER RESEARCH, Editorial Office, IIAR, 1st km Kapandritiou-Kalamou Rd., Kapandriti,
P.O. Box 22, Attiki, 19014, Greece. Tel & Fax: +30-22950-53389, e-mail: journals@iiar-anticancer.org

Special 2013 Offers to Authors of ANTICANCER RESEARCH

(These offers are open to all authors of articles published in Anticancer Research from 1981-2012 on a basis of priority and availability. Effective from January to December 2013).

Please complete and send this order form to:
ANTICANCER RESEARCH, International Institute of Anticancer Research,
1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece.

Special Subscription Order Form 2013

☐ I am one of the authors of the article published in Anticancer Research Vol., pp., year.

☐ Please enter my personal subscription to Anticancer Research 2013 (Volume 33) at the special Author’s rate of Euro 390.00 (print or online).

☐ Please send me previous Volume No(s) ............... at Euro 195.00 (print) per volume.

☐ Please enter my personal combined 2013 subscription to Anticancer Research (Volume 33) and IN VIVO (Volume 27) at Euro 560.00 (print or online).

☐ My payment is enclosed.

☐ Please send me an invoice.
(Prices include rapid delivery and insurance. Checks should be made payable to J.G. Delinasios, Athens, Greece).

Name and address: .............................................................................................................................................................................
Tel-Fax: ........................................................................................................................................................................................
e-mail: ......................................................................................................................................................................................
Date and signature: ...........................................................................................................................................................................
General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.
- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.
- IN VIVO supports: (a) the aims and the research program of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389; e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR websites: www.iiar-anticancer.org and www.iv.iiarjournals.org

Selection of Recent Articles

- Proteomic Profiling to Identify Prognostic Biomarkers in Heart Failure. P.A. SCOTT, B. ZEIDAN, L.L. NG, M. ZEB, J.A. ROSENGARTEN, S. GARIBIS, N.P. CURZEN, J.M. MORGAN, P.A. TOWNSEND (Southampton; Leicester, UK; Athens, Greece)
- Diverging In Vitro Antibody Isotype Switching Preference in B-Lymphocytes from C57BL/6 and FVB Mice. A.G. PUTHIYAVEETIL, B. OKYERE, C.M. REILLY, D. CAUDELL (Blacksburg, VA, USA)
- The Zebrafish- Danio rerio – Is a Useful Model for Measuring the Effects of Small-molecule Mitigators of Late Effects of Ionizing Irradiation. M.W. EPPERLY, N. BAHARY, M. QUADER, V. DEWALD, J.S. GREENBERGER (Pittsburgh, PA, USA)
- Breast Cancer: Mechanisms Involved in Action of Phytoestrogens and Epigenetic Changes. A. DAGDEMIR, J. DURIF, M. NGOLLO, Y.-J. BIGNON, D. BERNARD-GALLON (Clermont-Ferrand, France)
- Positron-emission Tomography (PET) Imaging Agents for Diagnosis of Human Prostate Cancer: Agonist vs. Antagonist Ligands. P.K. NANDA, B.E. WIENHOFF, T.L. ROLD, G.L. SIECKMAN, J.J. SMITH (Columbia; St. Louis, MO, USA)

FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST
Small Cell Carcinoma of the Colon Arising in a Carcinoid Tumor. M.W. SAIF (Boston, MA, USA) ........ 1713

Factors Predicting Trastuzumab-related Cardiotoxicity in a Realworld Population of Women with HER2+ Breast Cancer. D. NAUMANN, V. RUSIUS, C. MARGIOTTA, A. NEVILL, A. CARMICHAEL, D. REA, M. SINTLER (Westmidlands; Birmingham; Walsall, UK) .......................................................................................................................... 1717

Single-dose Palonosetron and Dose-reduced Regimen of Dexamethasone in Preventing Nausea and Vomiting by Anthracycline-including Chemotherapy in Patients with Early Breast Cancer. U. PACETTI, E. VELTRI, S.I.S. FATTORUSO, F. D’ASSISI CARDILLO, S. EVANGELISTA, F. COGNETTI, A. FABI (Terracina; Latina; Gaeta; Rome, Italy) ............................................................................................................ 1721

Thrombocytosis Has a Negative Prognostic Value in Lung Cancer. A. MARÁZ, J. FURÁK, Z. VARGA, Z. KAHÁN, L. TISZLAVICZ, K. HIDEGHITY (Szeged, Hungary) ........................................................... 1725

Expression of MAGE A1-6 and the Clinical Characteristics of Papillary Thyroid Carcinoma. H.S. LEE, S.W. KIM, J.C. HONG, S.B. JUNG, C.-H. JEON, J.W. PARK, S.Y. PARK, K.D. LEE (Busan; Daegu, Chungju, South Korea) ................................................................................................................... 1731


Traditional Serrated Adenoma in a Patient with Barrett’s Esophagus. C.A. RUBIO, K. TANAKA, R. BEFRITS (Stockholm, Sweden) .......................................................... 1743


Adenocarcinoma ExGoblet Cell Carcinoid in a Renal Transplant Patient: A Case Report and Review of the Literature. M.W. SAIF (Boston, MA, USA) .................................................................................. 1753

Cone Beam Computed Tomography in the Differential Diagnosis of Mental Neuropathy (Numb Chin Syndrome) in Metastatic Colon Cancer. R.E. FRIEDRICH, M. HEILAND, A.T. ASSAF, B. RIECKE (Hamburg, Germany) .......................................................... 1757

Airway Stenting for Tracheal Obstruction Due to Lymph Node Metastasis of Hepatocellular Carcinoma. Y. HAMAI, J. HIHARA, Y. AOKI, J. TAOMOTO, I. KISHIMOTO, Y. KOYABASHI, Y. MIYATA, H. AIKATA, K. CHAYAMA, M. OKADA (Hiroshima, Japan) .......................................................... 1761

Response to Chemotherapy in Metastatic Colorectal Cancer After Exposure to Oxaliplatin in the Adjuvant Setting. L.-C. MOREAU, R. RAJAN, M.P. THIRLWELL, T. ALCINDOR (Montreal, QC, Canada) ............ 1765

Usefulness of Circulating Tumor Cells after Preliminary Chemotherapy for Prediction of Response to Further Anticancer Therapy in Patients with Initially Unresectable Metastatic Colorectal Cancer. K. NEKI, H. KAWAHARA, K. WATANABE, Y. TOYAMA, T. AKIBA, K. YANAGA (Chiba; Tokyo, Japan) .......................................................... 1769

Hypofractionated Stereotactic Radiotherapy with the Hypoxic Sensitizer AK-2123 (Sanazole) for Reirradiation of Brain Metastases: A Preliminary Feasibility Report. H. YAMAZAKI, S. NAKAMURA, T. NISHIMURA, N. KODANI, T. TSUBOKURA, T. KIMOTO, H. SIHOMI, N. AIBE, K. YOSHIDA, M. KOIZUMI, T. KAGIYA (Kyoto; Uji, Kyoto; Takatsuki; Suita, Osaka, Japan) .......................................................... 1773


Errata ............................................................................................................................................ 1783


Phase II Study of Bevacizumab and Temsirolimus Combination Therapy for Recurrent Glioblastoma Multiforme. U. LASSEN, M. SORENSEN, T.B. GAZIEL, B. HASSELBALCH, H.S. POULSEN (Copenhagen, Denmark) ................................................................. 1657

The Role of Completion Surgery After Concurrent Radiochemotherapy in Locally Advanced Stages IB2-IIIB Cervical Cancer. E. CHEREAU, C. DE LA HOSSERAYE, M. BALLESTER, L. MONNIER, R. ROUZIER, E. TOBOUL, E. DARAI (Paris; Marseille, France) ............................................................................................................. 1661

Adipose Tissue Fatty Acid Composition in Greek Patients with Breast Cancer versus Those with Benign Breast Tumors. E. DE BREE, G. MAMALAKIS, E. SANIDAS, C. HATZIS, I. ASKOXYLAKIS, M. DASKALAKIS, V. CHARALAMPAKIS, G. TSIBINOS, D.D. TSIFTSIS, A. KAFATOS (Heraklion, Greece) ............................................................................................................. 1667


Comparison of Calculated Dose by Helical Tomotherapy Treatment Planning Machine and Measured Dose of Radiophotoluminescence Glass Dosimeter in Lung Lesions Using Rando Phantom. H. YAMAZAKI, K. IWAMA, T. NISHIMURA, Y. IWA, N. AIBE, T. TAKENAKA, S. MIYAKE, E. TANAKA, K. YOSHIDA, Y. OOTA, H. IKENO, S. NAKAMURA, H. OKABE (Kyoto; Uji, Kyoto; Osaka City, Osaka, Japan) ............................................................................................................. 1679

Intensity-modulated Radiation Therapy with Hypoxic Sensitizer AK-2123 (Sanazole) for Glioblastoma Multiforme Using Simultaneous Integrated Boost Technique. H. YAMAZAKI, S. NAKAMURA, T. NISHIMURA, H. OKABE, N. AIBE, K. YOSHIDA, T. KAGIYA (Kyoto; Uji, Kyoto, Takatsuki, Osaka, Japan) ............................................................................................................. 1685


Negative Impact of Surgical Site Infection on Long-term Outcomes after Hepatic Resection for Colorectal Liver Metastases. K. HARUKI, H. SHIBA, Y. FUJIIWARA, K. FURUKAWA, S. WAKIYAMA, M. OGAWA, Y. ISHIDA, T. MISAWA, K. YANAGA (Tokyo, Japan) ............................................................................................................. 1697

Gene Mutations in Squamous Cell NSCLC: Insignificance of EGFR, KRAS and PIK3CA Mutations in Prediction of EGFR-TKI Treatment Efficacy. O. FIALA, M. PESEK, J. FINEK, L. BENESOVA, Z. BORTLICEK, M. MINARIK (Prague; Brno, Czech Republic) ............................................................................................................. 1705

Contents continued on the preceding page
Design and Evaluation of Novel Radiolabelled VIP Derivatives for Tumour Targeting. C. RANGGER, A. HELBOK, M. OCAK, T. RADOLF, F. ANDREAE, I.J. VIRGOLINI, E. VON GUGGENBERG, C. DECRISTOFORO (Innsbruck; Graz, Austria; Istanbul, Turkey) ............................................................ 1537

Influence of Gefitinib and Erlotinib on Apoptosis and c-MYC Expression in H23 Lung Cancer Cells. M. SUENAGA, M. YAMAMOTO, S. TABATA, S. ITAKURA, M. MIYATA, S. HAMASAKI, T. FURUKAWA (Kagoshima, Japan) ........................................................................................................................ 1547


Clinical Studies

EGFR and Phosphorylated EGFR in Relation to HPV and Clinical Outcome in Tonsillar Cancer. M. ROMANITAN, A. NÄSMAN, E. MUNCK-WIKLAND, T. DALIANIS, T. RAMQVIST (Stockholm, Sweden) ........................................................................................................................................... 1575

Clostridium septicum Can Cause Distant Myonecrosis in Patients with Ovarian Cancer. S. ZURMEYER, C. FOTOPOLU, J. SEHOULI, E. BRAICU, U. SCHLICHTING (Berlin, Germany) ........................................ 1585

Chromopertubation – Presentation of a Modification of the Standard Technique. E. PETRI, S. BERLIT, M. SÜTTERLIN, A. HORNEMANN (Mannheim, Germany) ... 1591


High-dose FOLFIRI, Surgery, and Radiofrequency Ablation for Patients with Unresectable Liver Metastases from Colorectal Cancer. M. HEBBAR, S. TRUANT, C. DESAUW, G. SERGENT-BAUDSON, S. CATTAN, G. PIESSSEN, F.-R. PRUVOT (Lille, France) .................................................................... 1603

Postoperative Survival of Lung Cancer Patients: Are There Predictors Beyond TNM? G. FRIEDEL, P. FRITZ, S. GOLETZ, R. KRISTEN, F. BRINKMANN, R. DIERKESMANN, M. SCHWAB, G. OTT, J. DIPPO, M.D. ALSCHER (Gerlingen; Stuttgart, Germany) ........................................................................ 1609


Delayed Radiotherapy for Patients with Localized Prostate Cancer: Validation by Propensity Score Matching. H. NAKAYAMA, A. KANEMOTO, K. KIKUCHI, K. MATSUKI, M. TOMOBE, S. TSUKAMOTO, H. TAKESHIMA, Y. OSHIRO, S. SUGAHARA, K. TOKUYUYE (Tsukuba; Ushika; Ryugasaki, Ibaraki; Tokyo, Japan) ........................................................................................................................................... 1629

Contents continued on the preceding page
β-Elemene Promotes Cisplatin-induced Cell Death in Human Bladder Cancer and Other Carcinomas. Q.Q. LI, G. WANG, H. LIANG, J.M. LI, F. HUANG, P.K. AGARWAL, Y. ZHONG, E. REED (Beihai, Guangxi, PR China; Bethesda; Baltimore, MD; Morgantown, WV, USA) ............................................................ 1421

Thrombospondin-1 Receptor Mediates Autophagy of RAS-expressing Cancer Cells and Triggers Tumour Growth Inhibition. W. KALAS, E. SWIDEREK, M. ŚWITALSKA, J. WIETRZYK, J. RAK, L. STRZĄDAŁA (Wroclaw, Poland; Montreal, QC, Canada) ............................................................ 1429


Murine Double Minute 2 and Its Association with Chemoradioresistance of Esophageal Squamous Cell Carcinoma. H. OKAMOTO, F. FUJISHIMA, Y. NAKAMURA, M. ZUGUCHI, G. MIYATA, T. KAMEI, T. NAKANO, K. KATSURA, S. ABE, Y. TANIYAMA, J. TESHIMA, M. WATANABE, A. SATO, N. OHUCHI, H. SASANO (Sendai, Miyagi, Japan) ............................................................ 1463

Chemosensitivity Induced by Down-regulation of MicroRNA-21 in Gemcitabine-resistant Pancreatic Cancer Cells by Indole-3-Carbinol. W.H. PAIK, H.R. KIM, J.K. PARK, B.J. SONG, S.H. LEE, J.-H. HWANG (Seoul; Seongnam, South Korea) ............................................................ 1473


Circulating Levels of Transforming Growth Factor-β (TGF-β) and Chemokine (C-X-C Motif) Ligand-1 (CXCL1) as Predictors of Distant Seeding of Circulating Tumor Cells in Patients with Metastatic Breast Cancer. R. DIVELLA, A. DANIELE, E. SAVINO, F. PALMA, A. BELLIZZI, F. GIOTTA, G. SIMONE, M. LIOCE, M. QUARANTA, A. PARADISO, A. MAZZOCCA (Bari, Italy) ............................................................ 1491

The Impact of Angio-associated Migratory Cell Protein (AAMP) on Breast Cancer Cells In Vitro and Its Clinical Significance. Y. YIN, A.J. SANDERS, W.G. JIANG (Cardiff, UK; Jinan, Shandong, PR China) ............................................................ 1499


Effect of an Extract of Withania somnifera Root on Estrogen Receptor-positive Mammary Carcinomas. K.F. KHAZAL, T. SAMUEL, D.L. HILL, C.J. GRUBBS (Tuskegee; Birmingham, AL, USA) ............................................................ 1519

Normal Mammary Fibroblasts Induce Reversion of the Malignant Phenotype in Human Primary Breast Cancer. A.-M. RÖMER, I. LÜHR, A. KLEIN, A. FRIEDL, S. SEBENS, F. RÖSEL, N. ARNOLD, A. STRAUSS, W. JONAT, M. BAUER (Kiel; Berlin, Germany; Madison, WI, USA) ............................................................ 1525

Contents continued on the preceding page
Characterization and Evaluation of Pre-clinical Suitability of a Syngeneic Orthotopic Mouse Ovarian Cancer Model. S. CHO, Y. SUN, A.P. SOISSON, M.K. DODSON, C.M. PETERSON, E.A. JARBOE, A.M. KENNEDY, M.M. JANAT-AMSBURY (Salt Lake City, UT, USA) ................................................................. 1317

Establishment and Evaluation of a Bead-based Luminex Assay Allowing Simultaneous Quantification of Equine IL-12 and IFN-γ. M.C. DURAN, S. WILLENBROCK, J.-M. V. MÜLLER, I. NOLTE, K. FEIGE, H.M. ESCOBAR (Hannover, Germany) ............................................................... 1325

Secretory Phospholipase A₂ Mediates Human Esophageal Adenocarcinoma Cell Growth and Proliferation via ERK 1/2 Pathway. M.R. SADARIA, J.A. YU, X. MENG, D.A. FULLERTON, T.B. REECE, M.J. WEYANT (Aurora, CO, USA) ........................................................................................................ 1337

Effects of Pyridine Analogs of Curcumin on Growth, Apoptosis and NF-κB Activity in Prostate Cancer PC-3 Cells. X. WEI, D. ZHOU, H. WANG, N. DING, X.-X. CUI, H. WANG, M. VERANO, K. ZHANG, A.H. CONNEY, X. ZHENG, Z.-Y. DU (Guangzhou; Jiangmen, Guangdong, PR China; Piscataway, NJ, USA) .... 1343

The Histone Deacetylase Inhibitor Trichostatin A Promotes Apoptosis and Antitumor Immunity in Glioblastoma Cells. E. HöRING, O. PODLIECH, B. SILKENSTEDT, I.A. ROTA, E. ADAMOPOULOU, U. NAUMANN (Tübingen, Germany) ...................................................................................... 1351

A Color-coded Imaging Model of the Interaction of αᵥ Integrin-GFP Expressed in Osteosarcoma Cells and RFP Expressing Blood Vessels in Gelfoam® Vascularized In Vivo. F. UEHARA, Y. TOME, S. YANO, S. MIWA, S. MII, Y. HIROSHIMA, M. BOUVET, H. MAEHARA, F. KANAYA, R.M. HOFFMAN (San Diego, CA; Okinawa, Japan) .......................................................... 1361

Dynamic Subcellular Imaging of Cancer Cell Mitosis in the Brain of Live Mice. M. MOMIYAMA, A. SUETSUGU, H. KIMURA, T. CHISHIMA, M. BOUVET, I. ENDO, R.M. HOFFMAN (San Diego, CA, USA; Yokohama, Japan) ......................................................... 1367

Single Cell Time-lapse Imaging of Focus Formation by the DNA Damage-Response Protein 53BP1 after UVC Irradiation of Human Pancreatic Cancer Cells. S. MIWA, Y. TOME, S. YANO, Y. HIROSHIMA, F. UEHARA, S. MII, H. KIMURA, K. HAYASHI, H. TSUCHIYA, M. BOUVET, E.V. EFIMOVA, R.M. HOFFMAN (San Diego, CA; Chicago, IL, USA; Okinawa; Kanazawa, Ishikawa, Japan) ......... 1373

ABCG2 Inhibitor YHO-13351 Sensitizes Cancer Stem/ Initiating-like Side Population Cells to Irinotecan. Y. SHISHIDO, S. UENO, R. YAMAZAKI, M. NAGAOKA, T. MAITSUZAKI (Kunitachi-shi, Tokyo, Japan) .... 1379

Combining Clecexob with Sorafenib Synergistically Inhibits Hepatocellular Carcinoma Cells In Vitro. T. MORISAKI, M. UMEBAYASHI, A. KIYOTA, N. KOYA, H. TANAKA, H. ONISHI, M. KATANO (Fukuoka, Japan) ........................................................................................................................................ 1387

Regression of Canine Cutaneous Histioctyoma: Reduced Proliferation or Increased Apoptosis? I. PIRES, A. ALVES, F.L. QUEIROGA, F. SILVA, C. LOPES (Vila Real; Porto, Portugal) ................................................................. 1397

Expression and Prognostic Significance of the Oncogenic K2P Potassium Channel KCNK9 (TASK-3) in Ovarian Carcinoma. A. INNAMAA, L. JACKSON, V. ASHER, G. VAN SHALKWYK, A. WARREN, D. HAY, A. BALI, H. SOWTER, R. KHAN (Derby, UK).................................................................................... 1401

Association of Copper Transporter Expression with Platinum Resistance in Epithelial Ovarian Cancer. H. YOSHIDA, M. TERAMAE, M. YAMAUCHI, T. FUKUDA, T. YASUI, T. SUMI, K.-I. HONDA, O. ISHIKO (Osaka, Japan) ................................................................. 1409

Heterogeneous Sensitivity of Hepatocellular Carcinoma to Sorafenib Revealed by the Short-term Culture of Tumor Fragments. C. GODIN, S. DUPONT, Z. EZZOUKRY, C. LOUANDRE, D. CHATELAIN, L. HENAUT, C. SABBAGH, J.-M. REGIMBEAU, J.-C. MAZIERE, J.-C. BARBARE, B. CHAUFFERT, A. GALMICHE (Amiens, France) ........................................................................................................ 1415